GlassScriptPhysician profile
Mark A Mahoney
NPI 1427028554
$5,188.98
in general payments reported to CMS, 2019-2025
35 companies · $809 in 2025
The $809 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $645 · 2021: $719 · 2022: $719 · 2023: $996 · 2024: $776 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,581.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,072.20 | 2019-2025 | |
| Abbvie INC. | $669.02 | 2021-2025 | |
| Novo Nordisk INC | $545.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $433.40 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.81 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $370.32 | 2019-2025 | Mounjaro, Zepbound, Reyvow |
| Allergan, INC. | $192.89 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $187.40 | 2020-2025 | Eliquis, Camzyos |
| Teva Pharmaceuticals USA, INC. | $150.04 | 2019-2023 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $140.68 | 2019-2024 | |
| Amgen INC. | $104.29 | 2020-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $97.50 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.31 | 2021-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.18 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $58.61 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $51.99 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $51.16 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $47.45 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $44.00 | 2021 | |
| Idorsia Pharmaceuticals US INC | $39.88 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $36.96 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.38 | 2022 | |
| Mylan Specialty L.P. | $31.63 | 2021-2023 | Yupelri |
| Ironshore Pharmaceuticals INC. | $30.94 | 2023-2024 | Jornay Pm |
| Harmony Biosciences LLC | $29.01 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $28.54 | 2025 | |
| Acadia Pharmaceuticals INC | $19.57 | 2023 | Nuplazid |
| Phathom Pharmaceuticals, INC. | $18.31 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $17.06 | 2019 | |
| Verona Pharma, INC. | $16.35 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $16.10 | 2021 | |
| Viatris Specialty LLC | $15.39 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $15.07 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.52 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mahoney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.